Science 11 December 1992: Vol. 258. no. 5089, pp. 1795 - 1798 DOI: 10.1126/science.1465616

Prev | Table of Contents | Next

Articles

Ligand Binding but Undetected Functional Response of FcR after Their Capture by T Cells via Trogocytosis.

D. Hudrisier, B. Clemenceau, S. Balor, S. Daubeuf, E. Magdeleine, M. Daeron, P. Bruhns, and H. Vie (2009)
J. Immunol. 183, 6102-6113
 |  Abstract »  |  Full Text »  |  PDF »

Activated CD11b+ CD15+ Granulocytes Increase in the Blood of Patients with Uveal Melanoma.

K. C. McKenna, K. M. Beatty, R. A. Bilonick, L. Schoenfield, K. L. Lathrop, and A. D. Singh (2009)
Invest. Ophthalmol. Vis. Sci. 50, 4295-4303
 |  Abstract »  |  Full Text »  |  PDF »

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

C. Carpenito, M. C. Milone, R. Hassan, J. C. Simonet, M. Lakhal, M. M. Suhoski, A. Varela-Rohena, K. M. Haines, D. F. Heitjan, S. M. Albelda, et al. (2009)
PNAS 106, 3360-3365
 |  Abstract »  |  Full Text »  |  PDF »

Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma.

J. Kline, I. E. Brown, Y.-Y. Zha, C. Blank, J. Strickler, H. Wouters, L. Zhang, and T. F. Gajewski (2008)
Clin. Cancer Res. 14, 3156-3167
 |  Abstract »  |  Full Text »  |  PDF »

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2-Positive Advanced Melanoma.

J. A. Sosman, C. Carrillo, W. J. Urba, L. Flaherty, M. B. Atkins, J. I. Clark, J. Dutcher, K. A. Margolin, J. Mier, J. Gollob, et al. (2008)
J. Clin. Oncol. 26, 2292-2298
 |  Abstract »  |  Full Text »  |  PDF »

Polymorphisms in the CD3Z Gene Influence TCR{zeta} Expression in Systemic Lupus Erythematosus Patients and Healthy Controls.

C. L. Gorman, A. I. Russell, Z. Zhang, D. Cunninghame Graham, A. P. Cope, and T. J. Vyse (2008)
J. Immunol. 180, 1060-1070
 |  Abstract »  |  Full Text »  |  PDF »

CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells.

Z.-Z. Yang, A. J. Novak, S. C. Ziesmer, T. E. Witzig, and S. M. Ansell (2007)
Blood 110, 2537-2544
 |  Abstract »  |  Full Text »  |  PDF »

Altered Immune Function during Long-Term Host-Tumor Interactions Can Be Modulated to Retard Autochthonous Neoplastic Growth.

T. J. Stewart and S. I. Abrams (2007)
J. Immunol. 179, 2851-2859
 |  Abstract »  |  Full Text »  |  PDF »

Monocyte/macrophage infiltration in tumors: modulators of angiogenesis.

A. E. M. Dirkx, M. G. A. oude Egbrink, J. Wagstaff, and A. W. Griffioen (2006)
J. Leukoc. Biol. 80, 1183-1196
 |  Abstract »  |  Full Text »  |  PDF »

CD8-Mediated Type 1 Antitumor Responses Selectively Modulate Endogenous Differentiated and Nondifferentiated T Cell Localization, Activation, and Function in Progressive Breast Cancer.

M. J. Dobrzanski, J. B. Reome, J. C. Hylind, and K. A. Rewers-Felkins (2006)
J. Immunol. 177, 8191-8201
 |  Abstract »  |  Full Text »  |  PDF »

FcR{gamma} Presence in TCR Complex of Double-Negative T Cells Is Critical for Their Regulatory Function.

C. W. Thomson, W. A. Teft, W. Chen, B. P.-L. Lee, J. Madrenas, and L. Zhang (2006)
J. Immunol. 177, 2250-2257
 |  Abstract »  |  Full Text »  |  PDF »

A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3{zeta}-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells.

A Hombach, C Schlimper, E Sievers, S Frank, H H Schild, T Sauerbruch, I G H Schmidt-Wolf, and H Abken (2006)
Gut 55, 1156-1164
 |  Abstract »  |  Full Text »  |  PDF »

Increased Caspase-3 Expression and Activity Contribute to Reduced CD3{zeta} Expression in Systemic Lupus Erythematosus T Cells.

S. Krishnan, J. G. Kiang, C. U. Fisher, M. P. Nambiar, H. T. Nguyen, V. C. Kyttaris, B. Chowdhury, V. Rus, and G. C. Tsokos (2005)
J. Immunol. 175, 3417-3423
 |  Abstract »  |  Full Text »  |  PDF »

Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma.

S. Wei, I. Kryczek, L. Zou, B. Daniel, P. Cheng, P. Mottram, T. Curiel, A. Lange, and W. Zou (2005)
Cancer Res. 65, 5020-5026
 |  Abstract »  |  Full Text »  |  PDF »

Glucose Availability Regulates IFN-{gamma} Production and p70S6 Kinase Activation in CD8+ Effector T Cells.

C. M. Cham and T. F. Gajewski (2005)
J. Immunol. 174, 4670-4677
 |  Abstract »  |  Full Text »  |  PDF »

The Low Affinity Fc Receptor for IgG Functions as an Effective Cytolytic Receptor for Self-Specific CD8 T Cells.

S. Dhanji, K. Tse, and H.-S. Teh (2005)
J. Immunol. 174, 1253-1258
 |  Abstract »  |  Full Text »  |  PDF »

Tim-3+ T-bet+ Tumor-Specific Th1 Cells Colocalize with and Inhibit Development and Growth of Murine Neoplasms.

W. J. Simmons, M. Koneru, M. Mohindru, R. Thomas, S. Cutro, P. Singh, R. H. DeKruyff, G. Inghirami, A. J. Coyle, B. S. Kim, et al. (2005)
J. Immunol. 174, 1405-1415
 |  Abstract »  |  Full Text »  |  PDF »

Human CD4+ Effector Memory T Cells Persisting in the Microenvironment of Lung Cancer Xenografts Are Activated by Local Delivery of IL-12 to Proliferate, Produce IFN-{gamma}, and Eradicate Tumor Cells.

L. Broderick, S. J. Yokota, J. Reineke, E. Mathiowitz, C. C. Stewart, M. Barcos, R. J. Kelleher Jr., and R. B. Bankert (2005)
J. Immunol. 174, 898-906
 |  Abstract »  |  Full Text »  |  PDF »

Modulation of cord blood CD8+ T-cell effector differentiation by TGF-{beta}1 and 4-1BB costimulation.

Y.-J. Kim, T. M. Stringfield, Y. Chen, and H. E. Broxmeyer (2005)
Blood 105, 274-281
 |  Abstract »  |  Full Text »  |  PDF »

Citrulline Can Preserve Proliferation and Prevent the Loss of CD3 {zeta} Chain Under Conditions of Low Arginine.

V. Bansal, P. Rodriguez, G. Wu, D. C. Eichler, J. Zabaleta, F. Taheri, and J. B. Ochoa (2004)
JPEN J Parenter Enteral Nutr 28, 423-430
 |  Abstract »  |  Full Text »  |  PDF »

Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses.

P. C. Rodriguez, D. G. Quiceno, J. Zabaleta, B. Ortiz, A. H. Zea, M. B. Piazuelo, A. Delgado, P. Correa, J. Brayer, E. M. Sotomayor, et al. (2004)
Cancer Res. 64, 5839-5849
 |  Abstract »  |  Full Text »  |  PDF »

T-cell receptor-induced phosphorylation of the {zeta} chain is efficiently promoted by ZAP-70 but not Syk.

M. Steinberg, O. Adjali, L. Swainson, P. Merida, V. D. Bartolo, L. Pelletier, N. Taylor, and N. Noraz (2004)
Blood 104, 760-767
 |  Abstract »  |  Full Text »  |  PDF »

Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance.

M. Y. Mapara and M. Sykes (2004)
J. Clin. Oncol. 22, 1136-1151
 |  Abstract »  |  Full Text »  |  PDF »

T cell receptor {zeta} reconstitution fails to restore responses of T cells rendered hyporesponsive by tumor necrosis factor {alpha}.

J. M. Clark, A. E. Annenkov, M. Panesar, P. Isomaki, Y. Chernajovsky, and A. P. Cope (2004)
PNAS 101, 1696-1701
 |  Abstract »  |  Full Text »  |  PDF »

Tc1 and Tc2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses.

M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, and R. W. Dutton (2004)
J. Immunol. 172, 1380-1390
 |  Abstract »  |  Full Text »  |  PDF »

Characterization of Defective CD4-CD8- T Cells in Murine Tumors Generated Independent of Antigen Specificity.

R. M. Prins, F. Incardona, R. Lau, P. Lee, S. Claus, W. Zhang, K. L. Black, and C. J. Wheeler (2004)
J. Immunol. 172, 1602-1611
 |  Abstract »  |  Full Text »  |  PDF »

Effector Cell-Derived Lymphotoxin {alpha} and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases.

M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, J. C. Hylind, and R. W. Dutton (2004)
Cancer Res. 64, 406-414
 |  Abstract »  |  Full Text »  |  PDF »

T Cell Rewiring in Differentiation and Disease.

S. Krishnan, D. L. Farber, and G. C. Tsokos (2003)
J. Immunol. 171, 3325-3331
 |  Full Text »  |  PDF »

Effects of Local Injection of ex Vivo Expanded Autologous Tumor-specific T Lymphocytes in Cases with Recurrent Malignant Gliomas.

K. Tsuboi, K. Saijo, E. Ishikawa, H. Tsurushima, S. Takano, Y. Morishita, and T. Ohno (2003)
Clin. Cancer Res. 9, 3294-3302
 |  Abstract »  |  Full Text »  |  PDF »

Nitric Oxide-Independent CTL Suppression during Tumor Progression: Association with Arginase-Producing (M2) Myeloid Cells.

Y. Liu, J. A. Van Ginderachter, L. Brys, P. De Baetselier, G. Raes, and A. B. Geldhof (2003)
J. Immunol. 170, 5064-5074
 |  Abstract »  |  Full Text »  |  PDF »

Genetic changes occurring in established tumors rapidly stimulate new antibody responses.

M. T. Spiotto, M. A. Reth, and H. Schreiber (2003)
PNAS 100, 5425-5430
 |  Abstract »  |  Full Text »  |  PDF »

The FcR{gamma} Subunit and Syk Kinase Replace the CD3{zeta}-Chain and ZAP-70 Kinase in the TCR Signaling Complex of Human Effector CD4 T Cells.

S. Krishnan, V. G. Warke, M. P. Nambiar, G. C. Tsokos, and D. L. Farber (2003)
J. Immunol. 170, 4189-4195
 |  Abstract »  |  Full Text »  |  PDF »

Forced Expression of the Fc Receptor {gamma}-Chain Renders Human T Cells Hyperresponsive to TCR/CD3 Stimulation.

M. P. Nambiar, C. U. Fisher, A. Kumar, C. G. Tsokos, V. G. Warke, and G. C. Tsokos (2003)
J. Immunol. 170, 2871-2876
 |  Abstract »  |  Full Text »  |  PDF »

Immunogene Therapy of Tumors with Vaccine Based on Xenogeneic Epidermal Growth Factor Receptor.

Y. Lu, Y.-q. Wei, L. Tian, X. Zhao, L. Yang, B. Hu, B. Kan, Y.-j. Wen, F. Liu, H.-x. Deng, et al. (2003)
J. Immunol. 170, 3162-3170
 |  Abstract »  |  Full Text »  |  PDF »

Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.

L. Luznik, J. E. Slansky, S. Jalla, I. Borrello, H. I. Levitsky, D. M. Pardoll, and E. J. Fuchs (2003)
Blood 101, 1645-1652
 |  Abstract »  |  Full Text »  |  PDF »

Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1.

C. E. Touloukian, W. W. Leitner, R. E. Schnur, P. F. Robbins, Y. Li, S. Southwood, A. Sette, S. A. Rosenberg, and N. P. Restifo (2003)
J. Immunol. 170, 1579-1585
 |  Abstract »  |  Full Text »  |  PDF »

Lack of Effector Cell Function and Altered Tetramer Binding of Tumor-Infiltrating Lymphocytes.

U. Blohm, E. Roth, K. Brommer, T. Dumrese, F. M. Rosenthal, and H. Pircher (2002)
J. Immunol. 169, 5522-5530
 |  Abstract »  |  Full Text »  |  PDF »

Expression of a "Self-"Antigen by Human Tumor Cells Enhances Tumor Antigen-specific CD4+ T-Cell Function.

C. E. Touloukian, W. W. Leitner, P. F. Robbins, Y. F. Li, X. Kang, R. Lapointe, P. Hwu, S. A. Rosenberg, and N. P. Restifo (2002)
Cancer Res. 62, 5144-5147
 |  Abstract »  |  Full Text »  |  PDF »

Reactive Oxygen Species Differentially Affect T Cell Receptor-signaling Pathways*.

S. Cemerski, A. Cantagrel, J. P. M. van Meerwijk, and P. Romagnoli (2002)
J. Biol. Chem. 277, 19585-19593
 |  Abstract »  |  Full Text »  |  PDF »

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia.

R. T. Costello, S. Sivori, E. Marcenaro, M. Lafage-Pochitaloff, M.-J. Mozziconacci, D. Reviron, J.-A. Gastaut, D. Pende, D. Olive, and A. Moretta (2002)
Blood 99, 3661-3667
 |  Abstract »  |  Full Text »  |  PDF »

Clinical Significance of Poor CD3 Response in Head and Neck Cancer.

T. Y. Shibuya, N. Nugyen, C. E. McLaren, K.-T. Li, W.-Z. Wei, S. Kim, G. H. Yoo, A. Rogowski, J. Ensley, and W. Sakr (2002)
Clin. Cancer Res. 8, 745-751
 |  Abstract »  |  Full Text »  |  PDF »

Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance.

L. T. Nguyen, A. R. Elford, K. Murakami, K. M. Garza, S. P. Schoenberger, B. Odermatt, D. E. Speiser, and P. S. Ohashi (2002)
J. Exp. Med. 195, 423-435
 |  Abstract »  |  Full Text »  |  PDF »

Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma.

S. S. Agarwala, J. Glaspy, S. J. O'Day, M. Mitchell, J. Gutheil, E. Whitman, R. Gonzalez, E. Hersh, L. Feun, R. Belt, et al. (2002)
J. Clin. Oncol. 20, 125-133
 |  Abstract »  |  Full Text »  |  PDF »

The Alternatively Spliced Domain TnFnIII A1A2 of the Extracellular Matrix Protein Tenascin-C Suppresses Activation-Induced T Lymphocyte Proliferation and Cytokine Production.

M. D. Puente Navazo, D. Valmori, and C. Ruegg (2001)
J. Immunol. 167, 6431-6440
 |  Abstract »  |  Full Text »  |  PDF »

Microenvironment Produced by Acute Myeloid Leukemia Cells Prevents T Cell Activation and Proliferation by Inhibition of NF-{kappa}B, c-Myc, and pRb Pathways.

A. G. S. Buggins, D. Milojkovic, M. J. Arno, N. C. Lea, G. J. Mufti, N. S. B. Thomas, and W. J. R. Hirst (2001)
J. Immunol. 167, 6021-6030
 |  Abstract »  |  Full Text »  |  PDF »

Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection.

J. Lieberman, P. Shankar, N. Manjunath, and J. Andersson (2001)
Blood 98, 1667-1677
 |  Abstract »  |  Full Text »  |  PDF »

Serotonin protects NK cells against oxidatively induced functional inhibition and apoptosis.

A. Betten, C. Dahlgren, S. Hermodsson, and K. Hellstrand (2001)
J. Leukoc. Biol. 70, 65-72
 |  Abstract »  |  Full Text »  |  PDF »

Activated Granulocytes and Granulocyte-derived Hydrogen Peroxide Are the Underlying Mechanism of Suppression of T-Cell Function in Advanced Cancer Patients.

J. Schmielau and O. J. Finn (2001)
Cancer Res. 61, 4756-4760
 |  Abstract »  |  Full Text »  |  PDF »

Interleukin 12-activated Lymphocytes Influence Tumor Genetic Programs.

F. Cavallo, E. Quaglino, L. Cifaldi, E. Di Carlo, A. André, P. Bernabei, P. Musiani, G. Forni, and R. A. Calogero (2001)
Cancer Res. 61, 3518-3523
 |  Abstract »  |  Full Text »

Specific Deficiency of p56lck Expression in T Lymphocytes from Type 1 Diabetic Patients.

S. Nervi, C. Atlan-Gepner, B. Kahn-Perles, P. Lecine, B. Vialettes, J. Imbert, and P. Naquet (2000)
J. Immunol. 165, 5874-5883
 |  Abstract »  |  Full Text »  |  PDF »

Cross-Presentation of Tumor Antigens to Effector T Cells Is Sufficient to Mediate Effective Immunotherapy of Established Intracranial Tumors.

G. E. Plautz, S. Mukai, P. A. Cohen, and S. Shu (2000)
J. Immunol. 165, 3656-3662
 |  Abstract »  |  Full Text »  |  PDF »

Human Immunodeficiency Virus-Specific Circulating CD8 T Lymphocytes Have Down-Modulated CD3zeta and CD28, Key Signaling Molecules for T-Cell Activation.

L. A. Trimble, P. Shankar, M. Patterson, J. P. Daily, and J. Lieberman (2000)
J. Virol. 74, 7320-7330
 |  Abstract »  |  Full Text »

Molecular mechanism of the impairment in activation signal transduction in CD4+ T cells from old mice.

T. Tamura, T. Kunimatsu, S.-T. Yee, O. Igarashi, M. Utsuyama, S. Tanaka, S.-i. Miyazaki, K. Hirokawa, and H. Nariuchi (2000)
Int. Immunol. 12, 1205-1215
 |  Abstract »  |  Full Text »  |  PDF »

CD3zeta and CD28 down-modulation on CD8 T cells during viral infection.

L. A. Trimble, L. W. Kam, R. S. Friedman, Z. Xu, and J. Lieberman (2000)
Blood 96, 1021-1029
 |  Abstract »  |  Full Text »  |  PDF »

T Cell Adoptive Immunotherapy of Newly Diagnosed Gliomas.

G. E. Plautz, D. W. Miller, G. H. Barnett, G. H. J. Stevens, S. Maffett, J. Kim, P. A. Cohen, and S. Shu (2000)
Clin. Cancer Res. 6, 2209-2218
 |  Abstract »  |  Full Text »

Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+ Cytotoxic T Lymphocytes.

A. D. Santin, P. L. Hermonat, A. Ravaggi, S. Bellone, S. Pecorelli, J. J. Roman, G. P. Parham, and M. J. Cannon (2000)
J. Virol. 74, 4729-4737
 |  Abstract »  |  Full Text »

Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines.

I. Borrello, E. M. Sotomayor, F.-M. Rattis, S. K. Cooke, L. Gu, and H. I. Levitsky (2000)
Blood 95, 3011-3019
 |  Abstract »  |  Full Text »  |  PDF »

TCR V{beta} usage and clonality of T cells isolated from progressing and rejected tumor sites before and after in vitro culture.

R. A. Kurt, J. A. Park, S. F. Schluter, J. J. Marchalonis, and E. T. Akporiaye (2000)
Int. Immunol. 12, 639-646
 |  Abstract »  |  Full Text »  |  PDF »

Differential Recognition of a BCR/ABL Peptide by Lymphocytes from Normal Donors and Chronic Myeloid Leukemia Patients.

C. Bertazzoli, E. Marchesi, L. Passoni, R. Barni, F. Ravagnani, C. Lombardo, G. M. Corneo, P. Pioltelli, E. Pogliani, and C. Gambacorti-Passerini (2000)
Clin. Cancer Res. 6, 1931-1935
 |  Abstract »  |  Full Text »  |  PDF »

Granulocyte Macrophage Colony-stimulating Factor and Interleukin 4 Enhance the Number and Antigen-presenting Activity of Circulating CD14+ and CD83+ Cells in Cancer Patients.

M. D. Roth, B. J. Gitlitz, S. M. Kiertscher, A. N. Park, M. Mendenhall, N. Moldawer, and R. A. Figlin (2000)
Cancer Res. 60, 1934-1941
 |  Abstract »  |  Full Text »

Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo.

S. Radoja, T. D. Rao, D. Hillman, and A. B. Frey (2000)
J. Immunol. 164, 2619-2628
 |  Abstract »  |  Full Text »  |  PDF »

Resection of Solid Tumors Reverses T Cell Defects and Restores Protective Immunity.

S. Salvadori, G. Martinelli, and K. Zier (2000)
J. Immunol. 164, 2214-2220
 |  Abstract »  |  Full Text »  |  PDF »

Induction of CTL Responses by Simultaneous Administration of Liposomal Peptide Vaccine with Anti-CD40 and Anti-CTLA-4 mAb.

D. Ito, K. Ogasawara, K. Iwabuchi, Y. Inuyama, and K. Onoe (2000)
J. Immunol. 164, 1230-1235
 |  Abstract »  |  Full Text »  |  PDF »

Bypassing Immunization: Optimized Design of ""Designer T Cells"" against Carcinoembryonic Antigen (CEA)-expressing Tumors, and Lack of Suppression by Soluble CEA.

K. F. Nolan, C.-O. Yun, Y. Akamatsu, J. C. Murphy, S.-O. Leung, E. J. Beecham, and R. P. Junghans (1999)
Clin. Cancer Res. 5, 3928-3941
 |  Abstract »  |  Full Text »  |  PDF »

A transgenic mouse model to analyze CD8+ effector T cell differentiation in vivo.

N. Manjunath, P. Shankar, B. Stockton, P. D. Dubey, J. Lieberman, and U. H. von Andrian (1999)
PNAS 96, 13932-13937
 |  Abstract »  |  Full Text »  |  PDF »

Antitumor Cytotoxicity Mediated by Ligand-activated Human V{{alpha}}24 NKT Cells.

T. Kawano, T. Nakayama, N. Kamada, Y. Kaneko, M. Harada, N. Ogura, Y. Akutsu, S. Motohashi, T. Iizasa, H. Endo, et al. (1999)
Cancer Res. 59, 5102-5105
 |  Abstract »  |  Full Text »  |  PDF »

In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.

E. M. Sotomayor, I. Borrello, E. Tubb, J. P. Allison, and H. I. Levitsky (1999)
PNAS 96, 11476-11481
 |  Abstract »  |  Full Text »  |  PDF »

Expression of the T Cell Antigen Receptor zeta Chain following Activation Is Controlled at Distinct Checkpoints. IMPLICATIONS FOR CELL SURFACE RECEPTOR DOWN-MODULATION AND RE-EXPRESSION.

N. Bronstein-Sitton, L. Wang, L. Cohen, and M. Baniyash (1999)
J. Biol. Chem. 274, 23659-23665
 |  Abstract »  |  Full Text »  |  PDF »

Two Mechanisms for Tumor Evasion of Preexisting Cytotoxic T-Cell Responses: Lessons from Recurrent Tumors.

P. Zheng, S. Sarma, Y. Guo, and Y. Liu (1999)
Cancer Res. 59, 3461-3467
 |  Abstract »  |  Full Text »  |  PDF »

Vaccine therapy for cancer—fact or fiction?.

T.R.J. Evans and S.B. Kaye (1999)
QJM 92, 299-307
 |  Full Text »  |  PDF »

Primary Chemically Induced Tumors Induce Profound Immunosuppression Concomitant with Apoptosis and Alterations in Signal Transduction in T Cells and NK Cells.

S. Horiguchi, M. Petersson, T. Nakazawa, M. Kanda, A. H. Zea, A. C. Ochoa, and R. Kiessling (1999)
Cancer Res. 59, 2950-2956
 |  Abstract »  |  Full Text »  |  PDF »

Clinical Significance of Decreased {{zeta}} Chain Expression in Peripheral Blood Lymphocytes of Patients with Head and Neck Cancer.

I. Kuss, T. Saito, J. T. Johnson, and T. L. Whiteside (1999)
Clin. Cancer Res. 5, 329-334
 |  Abstract »  |  Full Text »  |  PDF »

Changes in the Fine Specificity of gp100(209-217)-Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor Residue.

T. M. Clay, M. C. Custer, M. D. McKee, M. Parkhurst, P. F. Robbins, K. Kerstann, J. Wunderlich, S. A. Rosenberg, and M. I. Nishimura (1999)
J. Immunol. 162, 1749-1755
 |  Abstract »  |  Full Text »  |  PDF »

CD4+ Lymphocytes Provide MUC1-Specific Tumor Immunity In Vivo That Is Undetectable In Vitro and Is Absent in MUC1 Transgenic Mice.

R. M. Tempero, M. L. VanLith, K. Morikane, G. J. Rowse, S. J. Gendler, and M. A. Hollingsworth (1998)
J. Immunol. 161, 5500-5506
 |  Abstract »  |  Full Text »  |  PDF »

Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes.

P. Romero, P. Rod Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J.-L. Chen, D. Lienard, J.-C. Cerottini, and V. Cerundolo (1998)
J. Exp. Med. 188, 1641-1650
 |  Abstract »  |  Full Text »  |  PDF »

Impaired Activation of NFkappa B in T Cells From a Subset of Renal Cell Carcinoma Patients Is Mediated by Inhibition of Phosphorylation and Degradation of the Inhibitor, Ikappa Balpha.

W. Ling, P. Rayman, R. Uzzo, P. Clark, H. J. Kim, R. Tubbs, A. Novick, R. Bukowski, T. Hamilton, and J. Finke (1998)
Blood 92, 1334-1341
 |  Abstract »  |  Full Text »  |  PDF »

De Novo-Developed T Cells Have Compromised Response to Existing Alloantigens: Using Ld-Specific Transgenic 2C T Cells as Tracers in a Mouse Heart Transplantation Model.

H. Luo, H. Chen, S. Qi, D. Loh, P. Daloze, A. Veillette, D. Xu, and J. Wu (1998)
J. Immunol. 161, 73-82
 |  Abstract »  |  Full Text »  |  PDF »

Immunologic Features of Tumor-Infiltrating Lymphocytes and Peripheral Blood Lymphocytes in Overian Cancer Patients.

T. Schondorf, H. Engle, C. M. Kurbacher, U. Brenne, H. Kolhagen, U.-J. Gohring, A. Scharl, and P. Mallmann (1998)
Reproductive Sciences 5, 102-107
 |  Abstract »  |  PDF »

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.

K. Staveley-O'Carroll, E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky (1998)
PNAS 95, 1178-1183
 |  Abstract »  |  Full Text »  |  PDF »

Changes in Expression of Signal Transduction Proteins in T Lymphocytes of Patients with Leprosy.

A. H. Zea, M. T. Ochoa, P. Ghosh, D. L. Longo, W. G. Alvord, L. Valderrama, R. Falabella, L. K. Harvey, N. Saravia, L. H. Moreno, et al. (1998)
Infect. Immun. 66, 499-504
 |  Abstract »  |  Full Text »  |  PDF »

Circulating CD8 T Lymphocytes in Human Immunodeficiency Virus-Infected Individuals Have Impaired Function and Downmodulate CD3zeta , the Signaling Chain of the T-Cell Receptor Complex.

L. A. Trimble and J. Lieberman (1998)
Blood 91, 585-594
 |  Abstract »  |  Full Text »  |  PDF »

Harnessing Syk Family Tyrosine Kinases as Signaling Domains for Chimeric Single Chain of the Variable Domain Receptors: Optimal Design for T Cell Activation.

C. J. Fitzer-Attas, D. G. Schindler, T. Waks, and Z. Eshhar (1998)
J. Immunol. 160, 145-154
 |  Abstract »  |  Full Text »  |  PDF »

Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy.

M. Wick, P. Dubey, H. Koeppen, C. T. Siegel, P. E. Fields, L. Chen, J. A. Bluestone, and H. Schreiber (1997)
J. Exp. Med. 186, 229-238
 |  Abstract »  |  Full Text »  |  PDF »

Adoptive Transfer of Anti-CD3-Activated CD4+ T Cells Plus Cyclophosphamide and Liposome-Encapsulated Interleukin-2 Cure Murine MC-38 and 3LL Tumors and Establish Tumor-Specific Immunity.

M. L. Saxton, D. L. Longo, H. E. Wetzel, H. Tribble, W. G. Alvord, L. W. Kwak, A. S. Leonard, C. D. Ullmann, B. D. Curti, and A. C. Ochoa (1997)
Blood 89, 2529-2536
 |  Abstract »  |  Full Text »  |  PDF »

Isolation of Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes That Lyse Reed-Sternberg Cells: Implications for Immune-Mediated Therapy of EBV+ Hodgkin's Disease.

A. P. Sing, R. F. Ambinder, D. J. Hong, M. Jensen, W. Batten, E. Petersdorf, and P. D. Greenberg (1997)
Blood 89, 1978-1986
 |  Abstract »  |  Full Text »  |  PDF »

Development and function of T cells in T cell antigen receptor/CD3 zeta  knockout mice reconstituted with Fcvarepsilon RI gamma.

C.-P. Liu, W.-J. Lin, M. Huang, J. W. Kappler, and P. Marrack (1997)
PNAS 94, 616-621
 |  Abstract »  |  Full Text »  |  PDF »

Transfer of the Interleukin-2 Gene Into Human Cancer Cells Induces Specific Antitumor Recognition and Restores the Expression of CD3/T-Cell Receptor Associated Signal Transduction Molecules.

A. Guarini, L. Riera, A. Cignetti, L. Montacchini, M. Massaia, and R. Foa (1997)
Blood 89, 212-218
 |  Abstract »  |  Full Text »  |  PDF »

Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta  chain of T-cell receptor complex and antigen-specific T-cell responses.

M. Otsuji, Y. Kimura, T. Aoe, Y. Okamoto, and T. Saito (1996)
PNAS 93, 13119-13124
 |  Abstract »  |  Full Text »  |  PDF »

CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer.

I. Hellstrom, J. A. Ledbetter, N. Scholler, Y. Yang, Z. Ye, G. Goodman, J. Pullman, M. Hayden-Ledbetter, and K. E. Hellstrom (2001)
PNAS 98, 6783-6788
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products